FNY Partners Fund’s Theravance Biopharma TBPH Stock Holding History

FNY Partners Fund’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,000	Closed	-$36K	–	1091
2017 Q1	$36K	Buy	+1,000	New	+$31.9K	﹤0.01%	811

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

FNY Partners Fund's TBPH Position: Q2 2017 in Review

FNY Partners Fund sold out of Theravance Biopharma (TBPH) in Q2 2017, closing a stake of 1,000 shares — an estimated $36K sold.

FNY Partners Fund first reported a position in TBPH in Q1 2017 and held it in 1 quarter. The position peaked at $36K in Q1 2017. 94 funds tracked by Wall St. Rank hold TBPH as of Q2 2017.

FNY Partners Fund reported no remaining Theravance Biopharma position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 1,000 Theravance Biopharma shares in Q2 2017, an estimated $36K.
FNY Partners Fund first reported a position in Theravance Biopharma in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's Theravance Biopharma position peaked at $36K in Q1 2017.
94 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.